Logo

It is a profound honor and privilege to assume the role of the 6th President of KGOG. I am deeply grateful for the trust and confidence you have placed in me, and I accept this responsibility with great humility and dedication. Since its founding in 2002, KGOG has grown into Korea's leading research society in the field of gynecologic oncology, thanks to the visionary leadership and tireless efforts of our past presidents, including the founding Chairman Prof. Kang Soon-beom, as well as Prof. Nam Joo-hyun, Prof. Kim Byoung-Gie, Prof. Kim Yong Man, and Prof. Kim Jae-Hoon. As we stand at a pivotal moment in our journey toward further advancement, I would like to outline three key areas of focus that I believe are essential for the continued growth and global competitiveness of our organization. 1. Advancing Innovation and Interdisciplinary Collaboration
Modern medicine increasingly demands cross-disciplinary collaboration. In line with this, gynecologic oncology research must evolve through integration with emerging fields such as molecular biology, artificial intelligence (AI), and precision medicine. By fostering innovation through convergence, we aim to lead the development of next-generation diagnostics and therapeutics. 2. Supporting the Next Generation of Researchers
One of KGOG's most important missions is to nurture the future leaders of medical research. We will actively create more opportunities for early-career researchers to participate in collaborative studies and academic exchanges, while strengthening our support to empower their potential. 3. Expanding International Academic Cooperation
We will enhance KGOG's global presence by establishing a stronger international research network and deepening collaboration with leading experts worldwide. Through this, we aim to ensure that the achievements of Korean researchers are recognized and respected on the global stage.

In addition, we will enhance the speed of the SRB (Scientific Review Board) process. While careful consideration is always required for protocol perfection, timely evaluation is essential, especially in the context of novel drug development or research involving new entities. We will work closely with the new SRB Chair to improve efficiency without compromising quality. KGOG now stands at the threshold of a new leap forward. In the face of increasing competition in the development of innovative treatments, it is imperative that we work together, leveraging our network and collective accomplishments to produce impactful research outcomes. Together, we are united in our mission to protect women's health and to develop better treatments for gynecologic cancers. Let us continue this journey with renewed commitment and solidarity. I pledge to devote myself fully to the advancement of our society and ask for your continued interest, cooperation, and support.
Thank you. Kim Dae-Yeon,
President, Korean Gynecologic Oncology Group (KGOG)
March 1, 2025